India’s OTC Potential, Regulatory Framework Entice Boehringer Ingelheim
This article was originally published in The Tan Sheet
The family-controlled German drug maker is preparing an entry into the Indian consumer health care segment, a market seeing a flurry of activity from competitors including GSK and Sanofi.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.